当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Preclinical evaluation of the efficacy of peptide targeting chemotherapy for the breast and other cancers

Chin-Tarng Lin

In our laboratory we have demonstrated that tumor-specific peptide-targeted chemotherapy is superior to conventional chemotherapy for the treatment of cancers. By using a phage-displayed random peptide library we have identified three 12-mer peptides: L-peptide, SP-94- peptide and PC5-52- peptides which can bind to breast and different cancer cell lines to meet several criteria for targeted drug delivery into cancer cells. In vitro study, those three peptides can bind specifically to the most cancer cell lines and some biopsy specimens; the peptide-linked liposome containing fluorescent substance is capable of binding to and translocate across cell membranes; in vivo study, these three peptides are able to bind and accumulate in the xenograft in SCID mice, but not in the mouse organs. Those peptide-linked liposomes containing doxorubicin not only can cause marked cytotoxicity to cancer cells, but also suppress markedly the xenograft growth (suppress more than 80-88% tumor size) in SCID mice with minimal adverse effect.